EdU assay results revealed that a decrease in ROCK2 levels reduced the proliferation of drug-resistant CCA cells treated with Pemigatinib, whereas UBA52-knockdown restored the proliferative capacity of these drug-resistant cells (Fig. 7C and S12D–F). This evidence concerns the gene ROCK2 and cholangiocarcinoma.